Cancer Diagnostics

  • warning: array_fill() [function.array-fill]: Number of elements must be positive in /homepages/29/d313822977/htdocs/oncogenetics.org/web/includes/database.inc on line 241.
  • warning: implode() [function.implode]: Invalid arguments passed in /homepages/29/d313822977/htdocs/oncogenetics.org/web/includes/database.inc on line 241.
  • warning: array_keys() [function.array-keys]: The first argument should be an array in /homepages/29/d313822977/htdocs/oncogenetics.org/web/modules/user/user.module on line 502.
  • user warning: You have an error in your SQL syntax; check the manual that corresponds to your MySQL server version for the right syntax to use near ')' at line 1 query: SELECT p.perm FROM role r INNER JOIN permission p ON p.rid = r.rid WHERE r.rid IN () in /homepages/29/d313822977/htdocs/oncogenetics.org/web/modules/user/user.module on line 502.

n/a

Pfizer Announces Positive Results From Phase 3 Study PROFILE 1007 Evaluating XALKORI® (crizotinib) In Previously Treated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer

Pfizer Inc. announced today that the PROFILE 1007 study met its primary endpoint, demonstrating that XALKORI® (crizotinib) significantly improved progression-free survival (PFS) when compared with pemetrexed or docetaxel, in previously treated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). PROFILE 1007 is the first randomized Phase 3 study in ALK-positive advanced NSCLC patients.

DNAVISION ORDERS SECOND ILLUMINA HISeq2000™ FOR COMMERCIAL USE

Brussels (Belgium) 27th August 2010 – DNAVision, Europe’s leading genetic analysis
service providers, is pleased to announce the acquisition beginning of August of an
additional Illumina HiSeq 2000 sequencing platform. The new system will be ready for
service to customer early October, just a few months after the first HiSeq system has
successfully entered into operation. Due to the high cost-effectiveness and sequencing
output, DNAVision uses the HiSeq 2000 systems mainly for human genome sequencing.

About DNAVision

DNAVISION ORDERS EUROPE’S FIRST HIScanSQ™ FOR COMMERCIAL USE

Brussels (Belgium) 17th May 2010 – DNAVision, one of Europe’s leading genetic analysis service providers, is pleased to announce the purchase of Illumina’s new HiScanSQ™ microarray and next-generation sequencing platform, which has officially been launched one month ago.

Illumina’s latest system will be installed in Gosselies’ facility and implemented in the highest quality certified environment (GMP, GLP, CLIA, CAP, ISO17025).

EntroGen Enters Into an Agreement With Childrens Hospital Los Angeles to Develop a Novel Genome-based Test for Ewing's Sarcoma

TARZANA, Calif., April 16, 2010 --- Today, EntroGen announced that it has entered into a collaboration and licensing agreement with the Childrens Hospital Los Angeles to develop a molecular diagnostic test for Ewing’s Sarcoma Family of tumors (EFT). The test will be based on a highly specific biomarker discovered at CHLA/USC and will offer oncologists a definitive diagnosis of EFT.

Beijing Genomics Institute-Hong Kong (BGI-HK) and DNAVISION partner on next generation sequencing technology

Belgian Embassy in Beijing, November 23th 2009 – DNAVision one of the European leading genetic analysis service provider, and the Beijing Genomics Institute-Hong Kong (BGI-HK, a spin-off of Beijing Genome Institute at Shenzhen, which is the third biggest genome centre in the world) announced today that they have entered into a strategic alliance to increase its position in Next Generation sequencing field.

DNAVision Announces Illumina CSPro Certification for Infinium Genotyping application

Liege, 20th November – DNAVision, a European-based genomic service provider, announced today that it has successfully completed Illumina CSPro™ certification for Infinium Genotyping, gaining entry to an elite group of Illumina genomics service providers globally. Illumina Inc., a San Diego-based company, provides leading-edge genetic analysis tools to genomics centers worldwide.

Knome Personal Genomics Service Expands to Include 93,000 Rare Mutations from the Human Gene Mutation Database Distributed by BIOBASE

Knome, a recognized pioneer in the personal genomics industry, announced today that it is incorporating information from The Human Gene Mutation Database (HGMD® - Cardiff University, UK) distributed by BIOBASE, into its genome interpretation services. With over 93,000 mutations and disease-related polymorphisms in more than 3,500 genes, HGMD is one of the world’s most comprehensive databases of medically relevant genetic variation. Typically used by large research institutions and pharmaceutical companies, this is the first time the genomic data in the HGMD is being made available as part of a consumer offering.

n/a

n/a